

## SUPPORTING INFORMATION

# Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity

Philipp Flury,<sup>a,‡</sup> Julian Breidenbach,<sup>b,‡</sup> Nadine Krüger,<sup>c,‡</sup> Rabea Voget,<sup>b</sup> Laura Schäkel,<sup>b</sup> Yaoyao Si,<sup>b</sup> Vesa Krasniqi,<sup>b</sup> Sara Calistri,<sup>a</sup> Matthias Olfert,<sup>a</sup> Katharina Sylvester,<sup>b</sup> Cheila Rocha,<sup>c</sup> Raphael Ditzinger,<sup>a</sup> Alexander Rasch,<sup>a</sup> Stefan Pöhlmann,<sup>c,d</sup> Thales Kronenberger,<sup>a,e,f</sup> Antti Poso,<sup>a,e</sup> Katharina Rox,<sup>g,h</sup> Stefan A. Laufer,<sup>a</sup> Christa E. Müller,<sup>b</sup> Michael Güttschow,<sup>b,\*</sup> and Thanigaimalai Pillaiyar<sup>a,\*</sup>

<sup>a</sup>Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany

<sup>b</sup>PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany

<sup>c</sup>Infection Biology Unit, German Primate Center, Leibniz Institute for Primate Research Göttingen, Kellnerweg 4, 37077 Göttingen, Germany

<sup>d</sup>Faculty of Biology and Psychology, University Göttingen, Göttingen 37073, Germany

<sup>e</sup>School of Pharmacy, University of Eastern Finland, Faculty of Health Sciences, Kuopio 70211, Finland

<sup>f</sup>Excellence Cluster "Controlling Microbes to Fight Infections" (CMFI), 72076 Tübingen, Germany

<sup>g</sup>Department of Chemical Biology, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany

<sup>h</sup>German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 38124 Braunschweig, Germany

<sup>‡</sup> These authors contributed equally.

### \*Corresponding authors


**Prof. Dr. Michael Güttschow:** – PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany; E-mail: [guetschow@uni-bonn.de](mailto:guetschow@uni-bonn.de).

**Dr. Thanigaimalai Pillaiyar:** – Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany. E-mail: [thanigaimalai.pillaiyar@uni-tuebingen.de](mailto:thanigaimalai.pillaiyar@uni-tuebingen.de).

## Table of Content

<b>1. GSH stability data</b>	S3
Figure S1: Graphical representation of the GSH studies of <b>9b</b> , <b>11b</b> and <b>11e</b>	S3
Table S1: GSH stability data, detected at 280 nm	S3
<b>2. Metabolic stability studies</b>	S4
Figure S2: Graphical representation of microsomal metabolic stability studies	S4
Table S2: Microsomal metabolic stability studies <b>11b</b>	S4
<b>3. Molecular modeling</b>	S5
Figure S3: RMSD from the protein's backbone and ligand's heavy atoms along the trajectory time	S5
<b>4. <sup>1</sup>H and <sup>13</sup>C NMR spectra</b> of representative compounds (Figures S4-24)	S6-26
<b>5. HPLC traces</b> of representative compounds	S27-36

## 1. GSH stability data for 11e, 11b, and 9b




**Figure S1:** Graphical representation of the GSH studies of **9b**, **11b**, and **11e**.

**Table S1:** GSH stability data, detected at 280 nm

<b>11e</b>			<b>11b</b>			<b>9b</b>		
time (min)	area (mAU*s)	%	time (min)	area (mAU*s)	%	time (min)	area (mAU*s)	%
0	5.1	100	0	58.0	100	0	75.2	100
20	4.0	79	20	54.7	94	20	74.3	99
40	5.7	111	40	56.4	97	40	72.7	97
60	4.9	96	60	56.3	97	60	73.7	98
80	5.0	99	80	56.0	96	80	74.2	99
100	6.5	128	100	58.3	100	100	74.7	99
140	6.4	126	120	60.5	104	120	75.0	100
160	4.0	78	140	56.2	97	140	73.0	97
180	4.7	92	160	58.3	100	160	73.4	98
200	5.1	100	180	56.4	97	180	73.6	98
220	4.9	96	200	58.3	100	200	76.1	101
240	5.0	98	220	56.3	97	220	75.2	100

## 2. Metabolic stability studies




**Figure S2:** Graphical representation of microsomal metabolic stability studies of **11b**.

**Table S2:** Microsomal metabolic stability studies of **11b**


time (min)	mouse liver microsomes			human liver microsomes		
	degradation (%)	SD	1/2 SD	degradation (%)	SD	1/2 SD
0	100.0	0.00	0.00	100.0	0.00	0.00
10	86.8	12.7	6.3	97.3	5.2	2.6
20	70.9	5.3	2.6	95.6	6.8	3.4
30	59.5	15.8	7.9	88.9	10.8	5.4
60	47.0	8.5	4.3	76.7	1.51	0.8
120	47.2	1.1	0.5	77.2	8.9	4.4



### 3. Molecular modeling




**Figure S3:** RMSD from the protein's backbone and ligand's heavy atoms along the trajectory time

#### 4. $^1\text{H}$ and $^{13}\text{C}$ NMR spectra







**Figure S5:** <sup>1</sup>H (400 MHz) & <sup>13</sup>C (101 MHz) NMR (CDCl<sub>3</sub>) spectra of 5-chloropyridin-3-yl (-3-(4-chlorophenyl)acryloyl)-L-leucyl-L-phenylalaninate (**5i**)





**Figure S6:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR (DMSO- $d_6$ ) spectra of (S)-2-cinnamamido-*N*-((S)-1-((1-cyanocyclopropyl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methylpentanamide (**6**)




**Figure S7:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR (DMSO- $d_6$ ) spectra of (S)-2-cinnamamido-N-((S)-1-(cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methylpentanamide (7)




**Figure S8:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (S)-2-cinnamamido-4-methyl-N-((S)-1-oxo-3-phenylpropan-2-yl)pentanamide (**9a**)




**Figure S9:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of *N*-((*S*)-4-methyl-1-oxo-1-(((*S*)-1-oxo-3-phenylpropan-2-yl)amino)pentan-2-yl)-1*H*-indole-2-carboxamide (**9b**)




**Figure S10:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (*S*)-2-(*3*-(3,5-dimethoxyphenyl)acrylamido)-4-methyl-*N*-((*S*)-1-oxo-3-phenylpropan-2-yl)pentanamide (**9c**)




**Figure S11:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (*S*)-2-cinnamamido-*N*-((*S*)-1-cyano-2-phenylethyl)-4-methylpentanamide (**11a**)




**Figure S12:** <sup>1</sup>H (400 MHz) & <sup>13</sup>C (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of *N*-((*S*)-1-((*S*)-1-cyano-2-phenylethyl)amino)-4-methyl-1-oxopentan-2-yl)-1*H*-indole-2-carboxamide (**11b**)





**Figure S13:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (*S*)-*N*-((*S*)-1-cyano-2-phenylethyl)-2-((*E*)-3-(3,5-dimethoxyphenyl)acrylamido)-4-methylpentanamide (**11c**)




**Figure S14:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (*S*)-2-(2-(4-chlorophenoxy) acetamido)-*N*-((*S*)-1-cyano-2-phenylethyl)-4-methylpentanamide (**11d**)




**Figure S15:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (*S*)-*N*-((*S*)-1-cyano-2-phenylethyl)-2-(2-(2,4-dichlorophenoxy)acetamido)-4-methylpentanamide (**11e**)




**Figure S16:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (S)-N-((S)-1-cyano-2-phenylethyl)-2-(2-(3-dimethylamino)phenoxy)acetamido-4-methylpentanamide (**11f**)




**Figure S17:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (*R,S*)-*N*-((*S*)-1-((*S*)-1-cyano-2-phenylethyl)amino)-4-methyl-1-oxopentan-2-yl)chromane-2-carboxamide (**11g**)





**Figure S18:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of *N*-((*S*)-1-(((*S*)-1-cyano-2-phenylethyl)amino)-4-methyl-1-oxopentan-2-yl)-5-phenylfuran-2-carboxamide (**11h**)





**Figure S19:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{DMSO}-d_6$ ) spectra of (*S*)-2-cinnamamido-4-methyl-*N*-((*S*)-1-phenyl-4-(phenylsulfonyl)but-3-en-2-yl)pentanamide (**12a**)





**Figure S20:** <sup>1</sup>H (400 MHz) & <sup>13</sup>C (101 MHz) NMR (DMSO-*d*<sub>6</sub>) spectra of *N*-(*S*)-4-methyl-1-oxo-1-((*S*)-1-phenyl-4-(phenylsulfonyl)but-3-en-2-yl)amino)pentan-2-yl)-1*H*-indole-2-carboxamide (**12b**)




**Figure S21:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR (DMSO- $d_6$ ) spectra of (*S*)-4-((*S*)-2-cinnamamido-4-methylpentanamido)-5-phenylpent-2-enamide (**13a**)



**Figure S22:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR (DMSO- $d_6$ ) spectra of *N*-((*S*)-1-(((*S*)-5-amino-5-oxo-1-phenylpent-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-1*H*-indole-2-carboxamid (**13b**)




**Figure S23:**  $^1\text{H}$  (400 MHz) &  $^{13}\text{C}$  (101 MHz) NMR ( $\text{CDCl}_3$ ) spectra of (*S*)-2-cinnamamido-*N*-((*S*)-4-cyano-1-phenylbut-3-en-2-yl)-4-methylpentanamide (**14a**)



**Figure S24:** <sup>1</sup>H (400 MHz) & <sup>13</sup>C (101 MHz) NMR (CDCl<sub>3</sub>) spectra of *N*-((*S*)-1-(((*S*)-4-cyano-1-phenylbut-3-en-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-1*H*-indole-2-carboxamide (**14b**)

## 5. HPLC traces

### Compound 5b



=====  
Area Percent Report  
=====


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.758	BB	0.1016	62.32738	9.13607	100.0000

Totals : 62.32738 9.13607

### Compound 5i



=====  
Area Percent Report  
=====


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.335	BB	0.1091	227.98138	31.99082	100.0000

Totals : 227.98138 31.99082

## Compound 6



=====  
=====  
Area Percent Report  
=====


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254.4 Ref=560.80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.235	BB	0.0764	685.66992	137.08678	100.0000

Totals : 685.66992 137.08678

## Compound 7



=====  
=====  
Area Percent Report  
=====


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254.4 Ref=560.80


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.171	BB	0.0832	157.33136	29.05354	100.0000

Totals : 157.33136 29.05354


## Compound 9a




## Compound 9b




### Compound 9c



### Compound 11a



### Compound 11b




#### Area Percent Report

Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.195	BB	0.0975	1193.95557	194.78198	98.6448
2	8.981	VB	0.1000	16.40281	2.39228	1.3552
Totals :				1210.35837	197.17426	

### Compound 11c




#### Area Percent Report

Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.731	VB	0.0826	452.26819	84.23004	97.2745
2	9.471	BB	0.0892	12.67204	2.07576	2.7255
Totals :				464.94023	86.30580	

## Compound 11d



=====  
Area Percent Report  
=====


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DADI A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.112	BB	0.0814	39.63363	7.07259	100.0000

Totals : 39.63363 7.07259

## Compound 11e



=====  
Area Percent Report  
=====


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DADI A, Sig=254,4 Ref=560,80


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.837	BB	0.0764	17.19309	3.31959	100.0000

Totals : 17.19309 3.31959


## Compound 11f



## Compound 11g



## Compound 11h



-----  
Area Percent Report  
-----


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.244	BB	0.0743	1695.46484	339.31561	95.4058
2	10.255	BB	0.0977	81.64434	12.56922	4.5942

Totals : 1777.10918 351.90484

## Compound 12a



-----  
Area Percent Report  
-----


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.956	BV	0.0795	248.28177	47.12888	65.7967
2	9.230	VB	0.1003	129.06532	18.30447	34.2033

Totals : 377.34709 65.43336

## Compound 12b




=====  
Area Percent Report  
=====

Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.934	BB	0.0702	94.15446	21.04728	57.7407
2	9.192	BB	0.0732	68.90974	14.05628	42.2593
Totals :					163.06419	35.10356

## Compound 13a



=====  
Area Percent Report  
=====


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.810	BB	0.0908	27.11792	4.59740	3.8175
2	8.110	BV	0.0902	365.03259	60.65736	51.3867
3	8.539	VB	0.0886	318.21301	54.12305	44.7958

Totals : 710.36353 119.37781

### Compound 13b



#### Area Percent Report


Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.080	BB	0.0775	89.28501	17.49447	48.0036
2	8.449	BB	0.0778	96.71154	18.85383	51.9964

Totals : 185.99655 36.34829

### Compound 14a



#### Area Percent Report

Sorted By : Signal  
Multiplier: : 1.0000  
Dilution: : 1.0000  
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=254,4 Ref=560,80

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.433	BV	0.0867	45.66756	7.75450	3.6275
2	8.458	BV	0.0738	627.28296	126.57775	49.8266
3	8.629	VB	0.0796	585.98193	110.93806	46.5459

Totals : 1258.93245 245.27031